文献速递胰腺与胆道疾病消化道肿瘤与早癌

CLDN18.2双特异性T细胞衔接器在胰腺癌临床前模型中调动效应T细胞与调节性T细胞产生抗肿瘤免疫应答

CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
PubMed 文献 · Gastroenterology · 2023-07-26

在胃癌和胰腺导管腺癌(PDAC)临床前模型中,CLDN18.2靶向的半衰期延长(HLE)BiTE分子AMG 910诱导特异性细胞毒性并产生显著抗肿瘤活性;单药及联合PD-1抑制剂可抑制肿瘤生长、延长生存;调节性T细胞(Treg)输注增强AMG 910疗效,BiTE治疗使Treg功能由免疫抑制转为免疫增强。

要点

  • AMG 910在胃癌和PDAC细胞系中诱导强效、特异性细胞毒性。
  • AMG 910单药及联合PD-1抑制剂在原位PDAC模型中抑制肿瘤生长并延长生存。
  • BiTE治疗使Treg功能由免疫抑制转为免疫增强,增强Teff细胞毒性。

核心结论

  • BiTE分子治疗可将Treg功能由免疫抑制转为免疫增强,从而在免疫「冷」肿瘤中产生抗肿瘤活性。

研究设计与样本

  • 在胃癌和PDAC临床前模型中评估CLDN18.2靶向半衰期延长(HLE)BiTE分子AMG 910的活性,并在CLDN18.2-HLE-BiTE存在下共培养Treg与Teff。

主要发现

  • AMG 910在胃癌和PDAC细胞系中诱导强效、特异性细胞毒性。
  • 在GSU和SNU-620胃癌异种移植模型中,AMG 910衔接人CD3+ T细胞与肿瘤细胞,产生显著抗肿瘤活性。
  • 在原位Panc4.14 PDAC模型中,AMG 910单药及联合PD-1抑制剂均抑制肿瘤生长并增强生存。
  • 在Panc4.14模型中,Treg输注增强AMG 910的抗肿瘤疗效。
  • 在PDAC同系KPC模型中,小鼠替代CLDN18.2-HLE-BiTE(muCLDN18.2-HLE-BiTE)单用或联合抗PD-1抗体均显著抑制肿瘤生长。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: BiTE (bispecific T-cell engager) immune therapy has demonstrated clinical activity in multiple tumor indications, but its influence in the tumor microenvironment remains unclear. CLDN18.2 is overexpressed in solid tumors including gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC), both of which are characterized by the presence of immunosuppressive cells, including regulatory T cells (Tregs) and few effector T cells (Teffs). METHODS: We evaluated the activity of AMG 910, a CLDN18.2-targeted half-life extended (HLE) BiTE molecule, in GC and PDAC preclinical models and cocultured Tregs and Teffs in the presence of CLDN18.2-HLE-BiTE. RESULTS: AMG 910 induced potent, specific cytotoxicity in GC and PDAC cell lines. In GSU and SNU-620 GC xenograft models, AMG 910 engaged human CD3+ T cells with tumor cells, resulting in significant antitumor activity. AMG 910 monotherapy, in combination with a programmed death-1 (PD-1) inhibitor, suppressed tumor growth and enhanced survival in an orthotopic Panc4.14 PDAC model. Moreover, Treg infusion enhanced the antitumor efficacy of AMG 910 in the Panc4.14 model. In syngeneic KPC models of PDAC, treatment with a mouse surrogate CLDN18.2-HLE-BiTE (muCLDN18.2-HLE-BiTE) or the combination with an anti-PD-1 antibody significantly inhibited tumor growth. Tregs isolated from mice bearing KPC tumors that were treated with muCLDN18.2-HLE-BiTE showed decreased T cell suppressive activity and enhanced Teff cytotoxic activity, associated with increased production of type I cytokines and expression of Teff gene signatures. CONCLUSIONS: Our data suggest that BiTE molecule treatment converts Treg function from immunosuppressive to immune enhancing, leading to antitumor activity in immunologically "cold" tumors.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Xu Y, Fu J, Henderson M, et al. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Gastroenterology. 2023. PMID: 37507075. doi:10.1053/j.gastro.2023.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。